CD BioSignal Presents Diabetes and Metabolism Solutions for Life Science Research

CD BioSignal, a US provider of life sciences and CRO research products, recently presented a comprehensive panel of research solutions covering all aspects of diabetes and metabolism and the study of metabolic diseases to provide the scientific community with a better and deeper understanding of metabolic regulation.

Metabolism describes the series of chemical reactions in a living system. The goals of metabolism are the conversion of nutrients into energy and building blocks, and the elimination of nitrogenous wastes. Metabolic processes are tightly controlled by cell signaling pathways to maintain metabolic homeostasis of the system. One of the hallmarks of cancer is altered metabolic patterns.

Metabolic pathways are a series of chemical reactions in metabolism, which are catalyzed by a sequence of enzymes. However, metabolic signaling pathways refer to the transductions of cell signaling that respond to the metabolic state and regulate cellular events to maintain cellular and organic homeostasis. Deregulation of these pathways is associated with metabolic diseases such as obesity, type 2 diabetes, as well as cancer and aging.

CD BioSignal now offers various solutions for research on metabolism, such as the identification of regulators to identify the regulators of genes participating in certain metabolic signaling pathways, the characterization of regulators to study the molecular function of certain regulators in the pathways of Metabolic signaling and the study of the mechanisms used to study the regulatory mechanism of certain regulators. Other solutions such as phenotype analysis, generation of animal models, chemical screening and development of therapies are also offered by CD BioSignal.

These new series of solutions can be used to study metabolic signaling pathways, such as the insulin signaling pathway, the mTOR pathway and the AMPK pathway. For example, the insulin signaling pathway, which signals transduction that regulates glucose homeostasis through the control of glucose and lipid metabolism. When insulin is released from the beta cells of the pancreas in response to high levels of nutrients, it binds to the insulin receptor, which activates signaling transduction and leads to cellular processes that promote absorption. glucose, fatty acids and amino acids.

Insulin resistance, where cells do not respond normally to insulin, is the underlying cause of type 2 diabetes. It also has a strong correlation with neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease. With advanced technologies and dedicated scientists, CD BioSignal now provides its customers with research solutions to study the insulin signaling pathway and associated diseases.

“CD BioSignal is committed to meeting all your inquiries in the research of signaling pathways. We provide high quality reagents and complete solutions to support your innovative discoveries. These new products related to metabolism looking for solutions are economical, high-quality and hassle-free, and are available to our customers around the world. We guarantee to deliver our products and results on time, ”said Kristy J. Morris, Marketing Director at CD BioSignal.

Customers For more information on Diabetes and Metabolism Solutions, please visit CD BioSignal at https://www.cd-biosignal.com.

About CD BioSignal

CD BioSignal is a trusted research product provider and CRO based in New York City. With high quality reagents and comprehensive services, CD BioSignal is the one-stop-shop dedicated to researchers making advancements in studies of signaling pathways.

Source link

About Donald P. Hooten

Check Also

Fujifilm Renews Fellowship Fund at Harvard Medical School for Translational Science Research | News

CAMBRIDGE, Mass., December 20, 2021 (GLOBE NEWSWIRE) – FUJIFILM Holdings America Corporation (Fujifilm) today announced …